Oxford, UK – 23 June 2015 – OxSonics Limited (“OxSonics”) has entered into a long-term contract development and manufacturing partnership with Juniper Pharma Services Ltd. (“Juniper”). Juniper will support OxSonics in the formulation development, scale-up and GMP manufacturing of OxSonics’ proprietary injectable “sono-sensitive particles”.
OxSonics was established in July 2013 to develop and commercialise a range of medical devices including “SonoTran”, an innovative oncological drug delivery platform. SonoTran has the capability to overcome one of the greatest challenges facing solid tumour cancer therapy by delivering drugs throughout tumours, including to the areas that lie furthest from blood vessels. OxSonics’ proprietary injectable sono-sensitive particles are core to the SonoTran platform.
Juniper has an established track record of helping specialty companies develop new products and platforms. Its science led approach to projects mitigates risk whilst optimising formulation performance.
Dr Colin Story, OxSonics Ltd. CEO said: “We are delighted to be working with Juniper Pharma Services. Juniper has the range of expertise, skill and know-how to take innovative and novel technologies such as ours from a lab-scale environment through to GMP-grade and clinical-trial scale manufacture and supply.
“Given the innovative and novel nature of our ground-breaking technology, we need to work with a team of experts such as those at Juniper to develop and scale-up the manufacture of the technology. In addition, Juniper, on behalf of OxSonics, will manufacture the innovative technology for our planned clinical trials.”
Dr Nikin Patel, President at Juniper Pharma Services said: “We are very pleased that OxSonics has chosen us as its long-term partner to help develop its pioneering platform. Dr Story and his team have done a fantastic job to date and we trust our experts will add significant value to the project with regards to meeting future milestones.
“This type of project using cutting-edge technology and requiring specialist formulation development is very much in our DNA and what we are known for in the market. The added benefit for OxSonics is that Juniper operates on a single site, single team basis with fully integrated processes from early development through to clinical so we always develop with clinical production in mind, which helps us to spot and correct any issues early and saves time and money in the long run.”
– ENDS –
About OxSonics Limited
OxSonics was established in July 2013 to develop and commercialise ground-breaking advancements in the field of therapeutic ultrasound invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics “SonoTran” drug delivery platform has the capability to overcome one of the greatest challenges facing solid tumour cancer therapy by delivering drugs throughout tumours, including to the areas that lie furthest from blood vessels. SonoTran can be applied to any cancer drug. A major benefit of OxSonics’ technology is the ability to provide real-time on-screen feedback to the clinician as to where and when drug delivery is taking place. OxSonics is based in Oxford, UK.
For more information please visit: www.oxsonics.com.
About Juniper Pharma Services
Juniper Pharma Services Ltd., a wholly owned subsidiary of Juniper Pharmaceuticals, Inc., is a contract development and manufacturing organisation (CDMO) that specializes in early phase pharmaceutical development. Its early phase services extend from pre-formulation and formulation development to clinical trial manufacturing, with specialist knowledge on developing challenging molecules and complex compounds. Juniper Pharma Services is also renowned for its expertise and toolkit to analytically resolve some of the toughest issues during development and relating to intellectual property issues. The company’s services are dedicated to pharmaceutical, biopharmaceutical and healthcare companies across the globe.
For more information please visit www.juniperpharma.com.